Search Results - "Jaglowski, Samantha Mary"

Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial by Wang, Michael, Rossi, John M., Munoz, Javier, Goy, Andre, Locke, Frederick Lundry, Reagan, Patrick Michael, Jacobson, Caron A., Hill, Brian T, Holmes, Houston, Jaglowski, Samantha Mary, Peng, Weimin, Zheng, Lianqing, Fang, Xiang, Xue, Allen, Rao, Arati V., Bot, Adrian

“…Abstract only 3023 Background: ZUMA-2 is a Phase 2 study evaluating KTE-X19, an autologous anti-CD19 CAR T cell therapy, in pts with R/R MCL (1 – 5 prior…”
Get full text

Second cancer incidence in CLL patients receiving BTK inhibitors by Bond, David Alan, Huang, Ying, Fisher, James L, Ruppert, Amy S., Owen, Dwight Hall, Bertino, Erin Marie, Rogers, Kerry Anne, Bhat, Seema Ali, Jaglowski, Samantha Mary, Grever, Michael R., Byrd, John C., Maddocks, Kami J., Woyach, Jennifer Ann

“…Abstract only 7511 Background: Patients (pts) with chronic lymphocytic leukemia (CLL) suffer morbidity and mortality from CLL and increased risk for second…”
Get full text

Autologous stem cell transplant (ASCT) in myeloma to improve patient reported physical function and fatigue by Bhatt, Geetika, Benson, Don M., Efebera, Yvonne Adeduni, Hofmeister, Craig C., Jaglowski, Samantha Mary, Devine, Steven Michael, Wildes, Tanya Marya, Huang, Ying, Jones, Desiree, Rosko, Ashley Elizabeth

“…Abstract only 10044 Background: Patients with Multiple Myeloma (MM) report some of the poorest Health-related quality of life (HRQoL). Few studies show how…”
Get full text

Depth of response and progression free survival in CLL patients on ibrutinib by Sigmund, Audrey, Huang, Ying, Ruppert, Amy S., Ny, Fan, Lucas, Margaret, Chase, Weihong, Maddocks, Kami J., Rogers, Kerry Anne, Jaglowski, Samantha Mary, Andritsos, Leslie Ann, Awan, Farrukh Tauseef, Grever, Michael R., Byrd, John C., Woyach, Jennifer Ann

“…Abstract only…”
Get full text

ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma by Wang, Michael, Locke, Frederick Lundry, Munoz, Javier, Goy, Andre, Holmes, Houston Eccleston, Siddiqi, Tanya, Flinn, Ian, McSweeney, Peter A, Reagan, Patrick Michael, Hill, Brian Thomas, Jacobson, Caron A., Rizzieri, David A., Heffner, Leonard T., Jaglowski, Samantha Mary, Miklos, David Bernard, Shaughnessy, Paul, Unabia, Sherry, Rossi, John M., Jiang, Yizhou, Jain, Rajul K.

“…Abstract only…”
Get full text

Considerations for tisagenlecleucel dosing rationale by Awasthi, Rakesh, Mueller, Karen Thudium, Yanik, Gregory A., Tam, Constantine Si Lun, Rives, Susana, McGuirk, Joseph, Boyer, Michael W., Jäger, Ulrich, Baruchel, Andre, Myers, Gary Douglas, Borchmann, Peter, Jaglowski, Samantha Mary, Stefanski, Heather E, Bishop, Michael Russell, Waldron, Edward K, Hamilton, Jason, Cota, Mariana, Bubuteishvili-Pacaud, Lida, Waller, Edmund K.

“…Abstract only…”
Get full text

A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD) by Miklos, David Bernard, Arora, Mukta, Cutler, Corey S., Nakamura, Ryotaro, Juretic, Manuela, Li, Yunfeng, Styles, Lori Appel, James, Danelle Frances, Jaglowski, Samantha Mary

“…Abstract only…”
Get full text

A feasibility study of electronic geriatric assessment for real-time morbidity evaluation by Bhatt, Geetika, Hofmeister, Craig C., Efebera, Yvonne Adeduni, Benson, Don M., Sborov, Douglas Weston, Jaglowski, Samantha Mary, Devine, Steven Michael, Wildes, Tanya Marya, Jones, Desiree, Huang, Ying, Rosko, Ashley Elizabeth

“…Abstract only…”
Get full text

Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients by Woyach, Jennifer Ann, Ruppert, Amy S., Lozanski, Gerard, Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Abruzzo, Lynne, Gordon, Amber, Jones, Jeffrey Alan, Flynn, Joseph M., Jaglowski, Samantha Mary, Andritsos, Leslie A., Awan, Farrukh, Blum, Kristie A., Grever, Michael R., Johnson, Amy J., Byrd, John C., Maddocks, Kami J.

“…Abstract only…”
Get full text

A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases by Jaglowski, Samantha Mary, Jones, Jeffrey Alan, Flynn, Joseph M., Andritsos, Leslie A., Maddocks, Kami J., Woyach, Jennifer Ann, Blum, Kristie A., Grever, Michael R., Geyer, Susan Michelle, Heerema, Nyla A., Lozanski, Gerard, Stefanos, Mona, Hall, Nathan, Nagar, Veena, Munneke, Brian, West, Jamie-Sue, Neuenburg, Jutta, James, Danelle Frances, Johnson, Amy J., Byrd, John C.

“…Abstract only…”
Get full text

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases by Jaglowski, Samantha Mary, Jones, Jeffrey Alan, Flynn, Joseph M., Andritsos, Leslie A., Maddocks, Kami J., Blum, Kristie A., Grever, Michael R., Geyer, Susan Michelle, Woyach, Jennifer Ann, Johnson, Amy J, Heerema, Nyla A., Molnar, Erin, Stefanos, Mona, Devlin, Susan, Navarro, Tasheda, James, Danelle Frances, Lowe, Ann M., Hedrick, Eric, Byrd, John C.

“…Abstract only 6508 Background: Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that is critical for B-cell receptor (BCR) signaling in normal and…”
Get full text